Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
AssigneeSignal Pharmaceuticals, LLC
InventorsMark J. Suto, Leah M. Gayo, Moorthy S. S. Palanki, Lynn J. Ransone-Fong
Life of this patent
Estimating the term…
Abstract
Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are pyrimidine-containing compounds and, in one embodiment, are esters of the same. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.
Claims39
A compound having the structure:
- ##STR22## wherein R.sub.2 is R.sub.2a when R.sub.4 is R.sub.4a, and R.sub.2 is R.sub.2b when R.sub.4 is R.sub.4b ;
- R.sub.2b and R.sub.4a are selected from hydrogen, halogen and an unsubstituted or substituted C.sub.1-8 alkyl, C.sub.6-12 aryl, C.sub.7-12 aralkyl, C.sub.3-12 heterocycle or C.sub.4-16 heterocycle;
- R.sub.2a and R.sub.4b are selected from the following chemical moieties:
- ##STR23## R.sub.5 is selected from --C(.dbd.)OR.sub.7 and --C(.dbd.O)R.sub.8 ;
- R.sub.6 is selected from hydrogen, --CH.sub.3, --CH.sub.2 C.sub.6 H.sub.5, --F and --CF.sub.3 ;
- R.sub.7 is selected from hydrogen and a unsubstituted or substituted C.sub.1-8 alkyl, C.sub.6-12 aryl and C.sub.7-12 aralkyl;
- R.sub.8 is an unsubstituted or substituted C.sub.1-8 alkyl, C.sub.6-12 aryl or C.sub.7-12 aralkyl;
- R.sub.9 is selected from hydrogen and an unsubstituted C.sub.1-8 alkyl or C.sub.7-14 aralkyl;
- R.sub.10 and R.sub.11 are the same or different and independently selected from hydrogen and an unsubstituted or substituted C.sub.1-8 alkyl or C.sub.6-12 aryl;
- and
- n is an integer from 0 to 4 and each occurrence of A is a substituent independently selected from halogen, --OH, --R, --OR, --COOH, --COOR, --COR, --CONH.sub.2, --NH.sub.2, --NHR, --NRR, --SH, --SR, --SOOR, --SOOH and --SOR, where each occurrence of R is independently selected from an unsubstituted or substituted C.sub.1-8 alkyl, C.sub.6-12 aryl or C.sub.7-12 aralkyl.
A method for treating an inflammatory condition, comprising administering to a warm-blooded animal in need thereof an effective amount of a compound having the structure:
- ##STR28## wherein R.sub.2 is R.sub.2a when R.sub.4 is R.sub.4a, and R.sub.2 is R.sub.2b when R.sub.4 is R.sub.4b ;
- R.sub.2b and R.sub.4a are selected from hydrogen, halogen and an unsubstituted or substituted C.sub.1-8 alkyl, C.sub.6-12 aryl, C.sub.7-12 aralkyl, C.sub.3-12 heterocycle or C.sub.4-16 heterocycle;
- R.sub.2a and R.sub.4b are selected from the following chemical moieties:
- ##STR29## R.sub.5 is selected from --C(.dbd.O)OR.sub.7 and --C(.dbd.O)R.sub.8 ;
- R.sub.6 is selected from hydrogen, --CH.sub.3, --CH.sub.2 C.sub.6 H.sub.5, --F and --CF.sub.3 ;
- R.sub.7 is selected from hydrogen and a unsubstituted or substituted C.sub.1-8 alkyl, C.sub.6-12 aryl and C.sub.7-12 aralkyl;
- R.sub.8 is an unsubstituted or substituted C.sub.1-8 alkyl, C.sub.6-12 aryl or C.sub.7-12 aralkyl;
- R.sub.9 is selected from hydrogen and an unsubstituted C.sub.1-8 alkyl or C.sub.7-14 aralkyl;
- R.sub.10 and R.sub.11 are the same or different and independently selected from hydrogen and an unsubstituted or substituted C.sub.1-8 alkyl or C.sub.6-12 aryl;
- and
- n is an integer from 0 to 4 and each occurrence of A is a substituent independently selected from halogen, --OH, --R, --OR, --COOH, --COOR, --COR, --CONH.sub.2, --NH.sub.2, --NHR, --NRR, --SH, --SR, --SOOR, --SOOH and --SOR, where each occurrence of R is independently selected from an unsubstituted or substituted C.sub.1-8 alkyl, C.sub.6-12 aryl or C.sub.7-12 aralkyl.
Dependencies are inferred from the claim text.